LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

Kodu・Aktsiate loetelu・Cytokinetics Inc

Cytokinetics Inc

Avatud

SektorTervishoid

73.92 -3.74

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

73.7

Max

76.34

Põhinäitajad
By Trading Economics
Sissetulek	-23M -206M
Müük	1.6M 19M
Aktsiakasum	-1.67
Kasumimarginaal	-1,064.485
Töötajad	673
EBITDA	112K -180M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+30.73% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	2.2B 10B
Eelmine avamishind	77.66
Eelmine sulgemishind	73.92

Uudiste sentiment

By Acuity

26%

74%

44 / 344 Pingereas Healthcare

Cytokinetics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. mai 2026, 23:44 UTC

Market Talk

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

31. mai 2026, 23:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

31. mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

31. mai 2026, 23:36 UTC

Market Talk

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

31. mai 2026, 22:54 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

29. mai 2026, 23:08 UTC

Omandamised, ülevõtmised, äriostud

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29. mai 2026, 23:06 UTC

Omandamised, ülevõtmised, äriostud

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29. mai 2026, 20:53 UTC

Tulu

Oil Declines Lift Stocks to Fresh Records -- WSJ

29. mai 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

29. mai 2026, 20:33 UTC

Market Talk

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29. mai 2026, 20:11 UTC

Tulu

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29. mai 2026, 19:47 UTC

Tulu

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29. mai 2026, 19:36 UTC

Market Talk

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29. mai 2026, 19:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29. mai 2026, 19:34 UTC

Market Talk

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29. mai 2026, 19:22 UTC

Market Talk

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29. mai 2026, 19:05 UTC

Omandamised, ülevõtmised, äriostud

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29. mai 2026, 18:19 UTC

Market Talk

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29. mai 2026, 18:12 UTC

Omandamised, ülevõtmised, äriostud

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29. mai 2026, 18:11 UTC

Market Talk

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29. mai 2026, 18:10 UTC

Market Talk

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29. mai 2026, 17:55 UTC

Tulu

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29. mai 2026, 17:55 UTC

Market Talk

NEAR Protocol Nearly Doubles in May -- Market Talk

29. mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29. mai 2026, 17:00 UTC

Tulu

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

29. mai 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

29. mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29. mai 2026, 16:02 UTC

Market Talk

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29. mai 2026, 15:55 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Cytokinetics Inc Prognoos

Hinnasiht

By TipRanks

30.73% tõus

12 kuu keskmine prognoos

Keskmine 100.35 USD 30.73%

Kõrge 140 USD

Madal 67 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Cytokinetics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

18 ratings

Osta

Hoia

Müü

Põhineb 18 analüütiku instrumendi Cytokinetics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

44 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.